Intra-Cellular Therapies

Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in developing lumateperone, which is in Phase III clinical trial for the treatment of bipolar depression, as well as to treat autism spectrum disorder; and in additional neuropsychiatric indications, such as sleep disorders associated with neuropsychiatric and neurological disorders. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease and heart failure; ITI-1284-ODT-SL for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression and anxiety. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.

At Intra-Cellular Therapies, our mission is to develop transformational treatments that make a meaningful difference in the lives of people affected by diseases and disorders of the central nervous system. We believe we can make profound improvements in the lives of patients with such diseases and disorders.

Our vision is to become a leading player in the global neuroscience space and make a positive impact on the lives of those affected by CNS diseases and disorders.

Intra-Cellular Therapies has been recognized for its pioneering work in the neurological field with numerous awards, including the 2017 Prix Galien USA Best Biotechnology Product Award and the 2016 Best Biotechnology Company Award from IBLF company.